Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vyndaqel

Synexus South Africa research sites join Pfizer trial network

CRO's sites become the first in Africa to meet the pharma company's standards

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

Pfizer pulls late-stage trial of cancer drug in NHL

Inotuzumab ozogamicin fails to show survival benefit in phase III

- PMLiVE

Pfizer launches online home delivery service for Viagra

Partners with CVS/pharmacy on e-commerce initiative

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Pfizer cuts 2013 forecast after weak first quarter

Revenues down 9 per cent as key drugs face generic competition

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

- PMLiVE

Pfizer partners with hospital to research medicines for children

Children’s Hospital of Philadelphia joins CTI translational research network

- PMLiVE

Pfizer’s Bosulif gets conditional green light for CML in Europe

Follows US approval last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links